ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies

INGLEWOOD, Calif., May 12, 2022 /PRNewswire/ -- ImaginAb Inc., a market-leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced a new agreement with Invicro LLC, a global,...

Click to view original post